Effects of acarbose on fecal nutrients, colonic pH, and short-chain fatty acids and rectal proliferative indices

Metabolism: Clinical and Experimental

Volumn 45, Issue 9, 1996, Pages 1179-1187

  Holt, Peter R ^a   Atillasoy, Evren ^b   Lindenbaum, John ^b   Ho, Sam B ^b   Lupton, Joanne R ^b   McMahon, Donald ^b   Moss, Steven F ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETIC ACID; BUTYRIC ACID; DIACYLGLYCEROL; SHORT CHAIN FATTY ACID;

ARTICLE; CLINICAL ARTICLE; COLON FLORA; COLON TUMOR; CONTROLLED STUDY; CRYPT CELL; DIABETES MELLITUS; FECES; FECES MICROFLORA; HUMAN; HUMAN TISSUE; HYDROGEN BREATH TEST; ORAL DRUG ADMINISTRATION; PH; PRIORITY JOURNAL; RECTUM BIOPSY;

EID: 0029738643     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90020-7     Document Type: Article

References (51)

1. Clissold SP, Edwards C: Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35:214-243, 1988
2. Rodier M, Richard JL, Monnier L, et al: Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent (type II) diabetes mellitus. Diabete Metab 14:12-14, 1988
3. Chiasson JL, Josse RG, Hunt JA, et al: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 121:928-935, 1994
4. Jenkins DJA, Taylor RH, Goff DV, et al: Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 30:951-954, 1981
5. Caspary WF, Lembocke B, Creutzfeldt W: Delaying of carbohydrate absorption by glucosidase inhibitors, in Creutzfeldt W, Folsch U (eds): Delaying Absorption as a Therapeutic Principle in Metabolic Disease. Stuttgart, Germany, Thieme, 1983, pp 87-95
6. Kotler DP, Holt PR, Rosensweig NS: Modification of the breath hydrogen test: Increased sensitivity for the detection of carbohydrate malabsorption. J Lab Clin Med 100:795-805, 1982
7. Holt PR, Thea D, Yang MY, et al: Intestinal and metabolic responses to an α-glucosidase inhibitor in normal volunteers. Metabolism 37:1163-1170, 1988
8. Steinbach G, Reddy BS, Lupton J, et al: Effect of calcium supplementation on rectal epithelial hyperproliferation in intestinal bypass subjects. Gastroenterology 106:1162-1167, 1994
9. Folch J, Leek M, Sloane-Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509, 1975
10. Ferrari A: Nitrogen determination by a continuous digestion and analysis system. Ann NY Acad Sci 87:792-800, 1960
11. Benedict FG, Fox EL: A method for the determination of the energy values of food and excreta. J Biol Chem 67:783-787, 1925
12. Butler VP Jr, Tse-Eng D, Lindenbaum J, et al: The development and application of a radioimmunoassay for dihydrodigoxin, a digoxin metabolite. J Pharmacol Exp Ther 221:123-131, 1982
13. Dobkin JF, Saha JR, Butler VP Jr, et al: Digoxin-inactivating bacteria: Identification in human gut flora. Science 220:325-327, 1983
14. Steinbach G, Morotomi M, Nomoto K, et al: Calcium reduces the increased fecal 1,2-sn- content in intestinal bypass patients: A mechanism for altering colonic hyperproliferation. Cancer Res 54:1194-1197, 1994
15. Steinbach G, Lupton JR, Reddy BS, et al: Effect of calcium supplementation on rectal epithelial hyperproliferation in intestinal bypass patients. Gastroenterology 106:1162-1167, 1994
16. Lipkin M, Blattner WA, Fraumeni JR Jr, et al: Tritiated thymidine labeling distribution in the identification of hereditary predisposition to colon cancer. Cancer Res 43:1899-1904, 1983
17. Satterthwaite FW: An approximate distribution of estimates of variance components. Biometrics Bull 2:110-114, 1946
18. Coniff RF, Shapiro JA, Seaton TB, et al: Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 98:443-451, 1995
19. Coniff RF, Shapiro JA, Seaton TB: Long-term safety and efficacy of acarbose in the treatment of obese subjects with noninsulin dependent diabetes mellitus. Ann Intern Med 154:2442-2448, 1994
20. Newmark HL, Lupton JR: Determinants and consequences of colonic luminal pH: Implications for colon cancer. Nutr Cancer 14:161-173, 1990
21. Fini A, Roda A: Chemical properties of bile acids. IV. Acidity constants of glycine-conjugated bile acids. J Lipid Res 28:755-759, 1987
22. Newmark HL, Wargovich MS, Bruce WR: Colon cancer and dietary fat, phosphate and calcium. A hypothesis. J Natl Cancer Inst 72:1323-1325, 1984
23. Lapré JA, Termont DSML, Groen AK, et al: Lytic effects of mixed micelles of fatty acids and bile acids. Am J Physiol 263:G333-G337, 1992
24. Lee DYK, Lupton JR, Aukema HM, et al: Dietary fat and fiber alter rat colonic mucosal lipid mediators and cell proliferation. J Nutr 123:1808-1817, 1993
25. Kashtan H, Gregoire R, Bruce WR, et al: Effects of sodium sulfate on fecal pH and proliferation of colonic mucosa in patients at high risk for colon cancer. J Natl Cancer Inst 82:950-952, 1990
26. Roediger WEW: Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 21:793-798, 1980
27. Scheppach W: Effects of short chain fatty acids on gut morphology and function. Gut 35:535-538, 1994 (suppl 1)
28. Roediger WEW: The starved colon - diminished mucosal nutrition, diminished absorption, and colitis. Dis Colon Rectum 33:858-862, 1990
29. Sakata T: Effects of short-chain fatty acids on epithelial cell proliferation and mucus release in the intestine, in Roche AF (ed): Short-Chain Fatty Acids: Metabolism and Clinical Importance. Report of the Tenth Ross Conference on Medical Research. Columbia, OH, Ross Laboratories, 1991, pp 63-67
30. Newmark HL, Young W: Butyrate and phenylacetate as differentiating agents: Practical problems and opportunities. J Cell Biochem [Suppl] 22:247-253, 1995
31. Lipkin M: Biomarkers of increased susceptibility to gastrointestinal cancer: New application to studies of cancer prevention in human subjects. Cancer Res 48:235-245, 1988
32. Lipkin M, Levin B, Kim Y, et al: Intermediate biomarkers of precancer and their applications in chemoprevention. J Cell Biochem [Suppl] 16G:1-122, 1992
33. Cohen SM, Purtilo DT, Ellwein LB: Pivotal role of increased cell proliferation in human carcinogenesis. Mod Pathol 4:371-382, 1991
34. Ames BN, Gold LS: Endogenous mutagens and the causes of aging and cancer. Mutat Res 250:3-16, 1991
35. Lipkin M: Phase 1 and phase 2 proliferative lesions of colonic epithelial cells in diseases leading to colonic cancer. Cancer 34:878-888, 1974
36. Boffa LC, Lupton JR, Mariani MR, et al: Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats. Cancer Res 52:5906-5912, 1992
37. Lupton JR: Butyrate and colonic cytokinetics: Differences between in vitro and in vivo studies. Eur J Cancer Prev 4:373-378, 1995
38. Levitt MD: Production and excretion of hydrogen gas in man. N Engl J Med 281:122-127, 1969
39. Perman JA, Modler S, Olson A: Role of pH in production of hydrogen from carbohydrates by colonic bacterial flora. J Clin Invest 67:643-650, 1981
40. Hoffman J, Spengler M: Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients: The Essen Study. Diabetes Care 17:561-566, 1994
41. Scrimshaw NS, Murray EB: Adaptation of lactose-maldigesting individuals to milk and milk products. Am J Clin Nutr 48:1118-1119, 1988 (suppl)
42. Flourie B, Briet F, Florent C, et al: Can diarrhea induced by lactulose be reduced by prolonged ingestion of lactulose? Am J Clin Nutr 58:369-375, 1993
43. Van Berge Henegouwen GP, Van Der Werf SDJ, Ruben ATH: Effect of long term lactulose ingestion on secondary bile salt metabolism in man: Potential protective effect of lactulose in colonic carcinogenesis. Gut 28:675-680, 1987
44. Thornton JR, Heaton KW: Do colonic bacteria contribute to cholesterol gall-stone formation? Effects of lactulose on bile. Br Med J 282:1018-1020, 1981
45. Lindenbaum J, Rund DG, Butler VP, et al: Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy. N Engl J Med 305:789-794, 1981
46. Lindenbaum J, Tse-Eng D, Butler VP Jr, et al: Urinary excretion of reduced metabolites of digoxin. Am J Med 71:67-74, 1981
47. Luchi RJ, Gruber JW: Unusually large digitalis requirements: A study of altered digoxin metabolism. Am J Med 45:322-328, 1968
48. Morotomi M, Guillem JG, Weinstein IB: Production of diacylglycerol, an activator of protein kinase, by human intestinal microflora. Cancer Res 50:3595-3599, 1990
49. Morotomi M, LoGerfo P, Weinstein BI: Fecal excretion, uptake and metabolism by colon mucosa of diacylglycerol in rats. Biochem Biophys Res Comm 181:1028-1034, 1991
50. Weinstein BI: Cancer prevention: Recent progress and future opportunities. Cancer Res 51:5080-5085, 1991
51. Pickering JS, Lupton JR, Chapkin RS: Dietary fat, fiber and carcinogen alter fecal diacylglycerol composition and mass. Cancer Res 55:2293-2298, 1995